Quantitative prediction of mechanism-based inhibition caused by mibefradil in rats

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1255-1262

  Sekiguchi, Nobuo ^a   Kato, Motohiro ^a   Takada, Maiko ^a   Watanabe, Hiroo ^a   Takata, Shotaro ^a   Mitsui, Tetsuya ^a   Aso, Yoshinori ^a   Ishigai, Masaki ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C11; CYTOCHROME P450 3A2; ISOENZYME; MIBEFRADIL; MIDAZOLAM; RECOMBINANT ENZYME;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLIC RATE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; MALE; MIBEFRADIL; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 79959454480     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037903     Document Type: Article

References (32)

1. Bittner B, González RC, Isel H, and Flament C (2003) Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. Eur J Pharm Biopharm 56:143-146. (Pubitemid 36802057)
2. Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, and Booth-Genthe C (2006) Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34:1703-1712. (Pubitemid 44427473)
3. Chovan JP, Ring SC, Yu E, and Baldino JP (2007) Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica 37:459-473. (Pubitemid 46809112)
4. Ghosal A, Sadrieh N, Reik L, Levin W, and Thomas PE (1996a) Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin. Arch Biochem Biophys 332:153-162. (Pubitemid 26286144)
5. Ghosal A, Satoh H, Thomas PE, Bush E, and Moore D (1996b) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947. (Pubitemid 26314544)
6. Higashikawa F, Murakami T, Kaneda T, Kato A, and Takano M (1999) Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol 51:67-72. (Pubitemid 29097271)
7. Imaoka S, Terano Y, and Funae Y (1990) Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation. Arch Biochem Biophys 278:168-178. (Pubitemid 20121888)
8. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
9. Ito K, Ogihara K, Kanamitsu S, and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954. (Pubitemid 36759066)
10. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171. (Pubitemid 27191615)
11. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, and Sugiyama Y (2000) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419-426. (Pubitemid 30395296)
12. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, and Sugiyama Y (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891-1901.
13. Kose N, Yamamoto K, Sai Y, Isawa M, Suwa T, and Nakashima E (2005) Prediction of theophylline clearance in CCl4-treated rats using in vivo CYP1A2 and CYP3A2 contents assessed with the PKCYP test. Drug Metab Pharmacokinet 20:168-176.
14. Kuze J, Mutoh T, Takenaka T, Morisaki K, Nakura H, Hanioka N, and Narimatsu S (2009) Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice. Xenobiotica 39:871-880.
15. Lin JH, Sugiyama Y, Awazu S, and Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm 10:649-661. (Pubitemid 13112144)
16. Ogasawara A, Negishi I, Kozakai K, and Kume T (2009) In vivo evaluation of drug-drug interaction via mechanism-based inhibition by macrolide antibiotics in cynomolgus monkeys. Drug Metab Dispos 37:2127-2136.
17. Polasek TM, Elliot DJ, Lewis BC, and Miners JO (2004) Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996-1007. (Pubitemid 39612704)
18. Poulin P and Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
19. Sekiguchi N, Higashida A, Kato M, Nabuchi Y, Mitsui T, Takanashi K, Aso Y, and Ishigai M (2009) Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet 24: 500-510.
20. Sekiguchi N, Kato M, Takada M, Watanabe H, Higashida A, Sakai S, Ishigai M, and Aso Y (2008) In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats. Xenobiotica 38:368-381. (Pubitemid 351380285)
21. Shimada M, Murayama N, Nagata K, Hashimoto H, Ishikawa H, and Yamazoe Y (1997) A specific loss of growth hormone abolished sex-dependent expression of hepatic cytochrome P450 in dwarf rats: reversal of the profiles by growth hormone-treatment. Arch Biochem Biophys 337:34-42. (Pubitemid 27198052)
22. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
23. Shiraki H and Guengerich FP (1984) Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase, and epoxide hydrolase. Arch Biochem Biophys 235:86-96.
24. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283.
25. Venkatakrishnan K and Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33:845-852. (Pubitemid 40686639)
26. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4:423-459. (Pubitemid 37279366)
27. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266. (Pubitemid 38176944)
28. Welker HA, Wiltshire H, and Bullingham R (1998) Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 35:405-423. (Pubitemid 29010173)
29. Wiltshire HR, Harris SR, Prior KJ, Kozlowski UM, and Worth E (1992) Metabolism of calcium antagonist Ro 40-5967: a case history of the use of diode-array u.v. spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway. Xenobiotica 22:837-857.
30. Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Harris SR, Worth E, and Welker HA (1997a) Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica 27:557-571. (Pubitemid 27259701)
31. Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Madigan MJ, and Sharp SR (1997b) Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part II. Metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man. Xenobiotica 27:539-556. (Pubitemid 27259700)
32. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, and Iga T (2001) Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 29:443-452. (Pubitemid 32275559)